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Since the mid-nineties, research has been carried out at the Nuclear Medicine 
Department of the University Medical Center Utrecht on holmium-166 poly(L-lactic 
acid) microspheres (166HoPLLAMS). These microspheres are intended as an intra-
arterial microdevice for internal radiation therapy of patients with unresectable 
liver malignancies, and are currently under clinical investigation. For certain 
localized tumors, such as kidney and brain tumors, direct injection of radioactive 
microspheres into the tumor is the preferred approach. However, to date no 166Ho 
containing device specifically tailored to this application has been proposed yet. 
The aim of this dissertation is to describe the preparation and characterization 
of such a holmium-loaded radioablation device, followed by in vitro and in vivo 
stability studies, and in vivo efficacy experiments. In addition to the development of 
holmium-loaded microspheres, the preparation of holmium loaded nanoparticles is 
investigated.
Chapter 2 reviews the currently available literature on microsphere based 
radioembolization techniques for treatment of patients with chemorefractory, 
unresectable liver tumors. These microspheres are administered through a catheter 
which is selectively placed in the hepatic artery. The predominant arterial blood 
supply to hepatic malignancies is exploited to achieve a high tumor targeting. 
The use of yttrium-90 (90Y) labeled glass and resin microspheres for treatment of 
unresectable liver malignancies has shown very promising results. Almost 90% of 
patients show a response (stable disease, partial remission, or complete remission) 
to 90Y radioembolization of hepatic malignancies. The selective administration 
procedure is laborious, and physicians are forced to use surrogate particles to 
predict the biodistribution, due to the lack of quantitative imaging possibilities 
associated with the use of the pure beta emitter 90Y. This can be overcome by using a 
combined beta and gamma emitter, like rhenium-186, rhenium-188 or holmium-166. 
166HoPLLAMS were proposed as a further improvement of this radioembolization 
technique, and, in preclinical studies, this microdevice’s stability, safety and efficacy 
were extensively investigated. Holmium is ideally suited for radioembolization, since 
it can be visualized in vivo using both nuclear imaging, X-ray computed tomography 
(CT) and magnetic resonance imaging (MRI). Currently, these 166HoPLLAMS are under 
clinical evaluation in patients with chemorefractory, unresectable liver tumors.
Unfortunately, not all patients are amenable for intra-arterial radioembolization 
and these patients might benefit from intratumoral radioablation with radioactive 
sources, so called interstitial microbrachytherapy. 166HoAcAcMS were proposed 
as a microbrachytherapy device. In addition, the intratumoral administration of 
radioactive microspheres is not limited to liver tumors, but can be used in solid 
tumors in other organs as well.
Chapter 3 describes the preparation and characterization of holmium acetylaceto-
nate microspheres (HoAcAcMS): microspheres dedicated for intratumoral radioab-
lation. Since the injection volume is limited in solid tumors, the activity per sphere 
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should be as high as possible. Compared to the 166HoPLLAMS, the holmium content 
of the HoAcAcMS was 130% higher (44% w/w versus 19% w/w for the HoPLLAMS) 
which is considered sufficient for intratumoral radioablation. Chemical characteriza-
tion of these HoAcAcMS revealed a structural rearrangement of acetylacetonate 
around holmium during particle formation. Neither changes in the particle size nor 
in the particle surface were observed after neutron irradiation for up to six hours at 
a neutron flux of 5 x 1012 n cm-2 s-1. Additionally, it was found that the sensitivity on 
MRI and CT also increased due to the 2.5 fold holmium increase, which is expected 
to facilitate image-guided delivery of the HoAcAcMS in patients.
Chapter 4 presents the results of an in vitro and in vivo stability study of the 
HoAcAcMS. For the in vitro study, non-neutron irradiated and neutron irradiated 
HoAcAcMS were suspended in phosphate buffer, and the holmium content in buffer 
was determined at different timepoints. After incubation for 180 days in phosphate 
buffer, the release of holmium (3+) from the microspheres was 0.5 ± 0.2%. The 
microspheres were analyzed using elemental analysis, infrared spectroscopy (IR 
spectroscopy), time of flight secondary ion mass spectrometry (TOF-SIMS), and 
scanning electron microscopy. Elemental analysis, IR spectroscopy and TOF-SIMS 
showed that the acetylacetonate in the microspheres was replaced by phosphate 
within four days, creating a very stable complex. Interestingly, SEM showed that 
the particles retained their size and shape, irrespective of the incubation time. The 
in vivo stability was assessed after intratumoral administration of 166HoAcAcMS 
to VX-2 tumor-bearing rabbits. The holmium content in urine, faeces and blood 
was determined to assess leakage of holmium from the microspheres. The 
holmium content in all these samples was below the detection limit. The rabbits 
were terminated one month after administration of 166HoAcAcMS and histological 
analysis of the tumor tissue revealed intact microspheres amidst necrotic tissue. 
The holmium content in bone (piece of femur) was below the detection limit of 0.1 
ppm indicating no holmium had released from the microspheres. Altogether, it is 
concluded that 166HoAcAcMS are highly stable in vivo and therefore can be safely 
used for radioablation of liver malignancies.
Chapter 5 reports on a case series of three cats with inoperable liver tumors of 
different histotype (hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and 
malignant epithelial liver tumors (MELT) of unknown origin) which underwent 
treatment with 166HoAcAcMS, administered percutaneously under ultrasound 
guidance. Follow-up consisted of regular physical examinations and hematological 
and biochemical analyses. The 166HoAcAcMS were successfully administered, and 
the treatment was well tolerated by all animals. The clinical condition of the cats 
improved markedly, as did most biochemical and hematological parameters shortly 
after treatment resulting in the extension of life in good quality of all animals. The 
HCC cat was euthanized six months after the first administration due to disease 
progression, the CC cat succumbed four months after the first treatment due to the 
formation of a pulmonary embolism, whereas the MELT cat developed bacterial 
meningitis and was euthanized three months post treatment. This radioablation 
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technique appears to be efficacious and not associated with adverse side effects 
and therefore it is concluded that percutaneous intratumoral administration of 
radioactive 166HoAcAcMS is feasible in cats suffering from liver tumors.
Chapter 6 describes the use of intratumorally administered 166HoAcAcMS as a novel 
minimally-invasive treatment for kidney tumors. The efficacy of 166HoAcAcMS was 
compared to the intratumoral administration of saline in a renal cell carcinoma 
mouse model. Either five MBq 166HoAcAcMS in 10 µL or 10 µL saline was injected when 
the tumors were approximately 6 mm in size. After administration of 166HoAcAcMS, 
CT images were acquired on a dedicated small animal CT. At predefined time points 
post administration, the mice were sacrificed and the tumor, kidneys and liver, lungs, 
heart and spleen were excised. The tumor size was determined by measurement with 
digital calipers and the organs were measured using a dose calibrator, to determine 
the amount of radioactivity in the organs. The mice of the 166HoAcAcMS group 
showed an arrest in the tumor growth, whereas the tumors in the control group 
showed an exponential increase in tumor volume. Additionally, the multimodality 
imaging characteristics were exploited by performing micro CT, microSPECT and 
MR imaging on dedicated animal scanners. All imaging modalities showed a similar 
distribution of 166HoAcAcMS. The biodistribution of the 166HoAcAcMS as shown on 
the SPECT images was used to calculate a realistic dose distribution. Quantitative 
analysis of SPECT images, and the possibility to use these images for dosimetry is 
a fundamental advantage of the 166HoAcAcMS over other ablative techniques. This 
will improve the clinical application of this therapy, in terms of safety and efficacy.
Chapter 7 is dedicated to the preparation of another holmium containing 
radioablation device: HoAcAc nanoparticles (HoAcAcNP). From the previous in vivo 
experiments described in chapters 4, 5 and 6, it was concluded that intratumoral 
injections with 166HoAcAcMS (approximately 8 mm) are effective, yet premature 
settling of the 166HoAcAcMS in the syringe posed a problem. By substantially 
reducing the particle size, the sedimentation rate of particle suspension is reduced, 
which may contribute to a standardized, reproducible injection procedure. A second 
(theoretical) advantage of a particle size reduction is an improved intratumoral 
distribution, leading to a better dose delivery. Spherical nanoparticles with a smooth 
surface and a diameter of 0.08 ± 0.01 mm were obtained with a holmium content 
of 44% (w/w) using a solvent evaporation technique. The nanoparticles were stable 
and showed a holmium release of less than 2% after 72 h in HEPES 10 mM. Neutron 
irradiation for one hour at a neutron flux of 5 x 1012 n cm-2 s-1 neither affected the 
particle size nor particle surface morphology. Additionally, the sensitivity of the 
HoAcAcNP on MRI and CT was assessed and it was observed that the sensitivity on 
CT was similar to the sensitivity of the HoAcAcMS. The sensitivity on MRI decreased 
due to the substantially reduced particle size, yet was similar to the MR sensitivity of 
HoAcAcMS when the particles are clustered. This led to the visualization of as little 
as 1.5 µg of HoAcAcNP on MRI.
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Future perspectives
The main focus of this thesis was on HoAcAcMS which have been investigated 
in detail, and more insights into their formation, in vitro and in vivo stability, and 
efficacy have been obtained. However, a number of issues need to be addressed 
prior to the start of a phase I study in man. This thesis presents the work of a 
relatively short-term (one month) in vivo toxicity study, yet a longer in vivo toxicity 
study is required to evaluate the long-term effects of HoAcAcMS in tissue. 
Treatment of solid tumors by direct injection of 166HoAcAcMS should be accurate 
and safe, irrespective of the tumor location. To this end, an injection system that 
enables accurate, reproducible administration of 166HoAcAcMS has to be developed.
     In addition, this system has to shield both the beta particles and gamma rays 
to protect the physician from ionizing radiation in compliance with the as-low-as-
reasonably-achievable (ALARA) principle.
Another issue to be addressed is the number of injections per target volume. The 
maximum tissue range of the 166Ho beta particles is 8.7 mm, and consequently tumors 
larger than 2 cm require multiple injections to achieve >100 Gy dose throughout the 
tumor. Therefore, the number and positions of injections to obtain complete tumor 
kill in larger (>2 cm) tumors needs to be investigated and standardized. 
Apart from intratumoral injection HoAcAcMS may be used for transarterial 
hepatic radioembolization. For this modality, the particle size of HoAcAcMS needs 
to be increased from 15 mm to 25 – 30 mm, in order to obtain a particle size similar 
to the HoPLLAMS already in use. Potential advantages of the HoAcAcMS compared 
to HoPLLAMS rely on the higher holmium load per microsphere. Owing to the higher 
holmium content per sphere, similar amounts of activity can be administered in a 
lesser number of particles, thus reducing the risk of retrograde flow or stasis due to 
macro-embolization of hepatic vessels. Also, patient eligibility would be extended 
because patients suffering from portal vein thrombosis, which occurs in a high 
percentage of patients suffering from (primary) liver cancer, will then be allowed 
to receive holmium radioembolization treatment. The high holmium content of 
the HoAcAcMS allows for visualization on MRI of the relatively small amount of 
spheres used for the pretreatment scout dose. This might further pave the way for 
MR guided transcatheter radioembolization. The CT sensitivity of the HoAcAcMS 
might even allow for visualization of non-radioactive microspheres on the latest 
generation fluoroscopy systems currently used in angiography suites. This will 
further improve the image-guided transcatheter radioembolization treatment with 
holmium microspheres.
HoAcAc nanoparticles have also been prepared and characterized, and are 
proposed as a radioablation device that could be theorized to better penetrate 
tumorous tissue upon injection, but this has to be established. This can be 
investigated by comparing the intratumoral distribution of HoAcAc nanoparticles 
and HoAcAcMS following intratumoral injection.
Apart from this therapeutic application, the HoAcAc nanoparticles might be 
suitable as an MR contrast agent since their size is in the range of iron oxide particles 
(so-called superparamagnetic iron oxide (SPIO) particles 70 – 150 nm), which are 
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used for the detection of liver lesions. This requires a number of studies including 
cell uptake and toxicity studies to evaluate the feasibility of HoAcAc nanoparticles 
for this purpose.
A number of yet unexplored research possibilities in the field of holmium 
containing (micro)devices for potential diagnostic as well as therapeutic applications 
exist, and promises a bright future for these systems tagged with this fascinating 
element of the lanthanide group.
